[go: up one dir, main page]

WO1996037207A3 - Pharmaceutical compositions containing calcium sulfate - Google Patents

Pharmaceutical compositions containing calcium sulfate Download PDF

Info

Publication number
WO1996037207A3
WO1996037207A3 PCT/US1996/007874 US9607874W WO9637207A3 WO 1996037207 A3 WO1996037207 A3 WO 1996037207A3 US 9607874 W US9607874 W US 9607874W WO 9637207 A3 WO9637207 A3 WO 9637207A3
Authority
WO
WIPO (PCT)
Prior art keywords
calcium sulfate
compositions
disclosed
methods
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1996/007874
Other languages
French (fr)
Other versions
WO1996037207A2 (en
Inventor
Sohail Malik
Rolland F Hebert
Min Yee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biofrontiers Inc
Original Assignee
Biofrontiers Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/449,949 external-priority patent/US5683725A/en
Application filed by Biofrontiers Inc filed Critical Biofrontiers Inc
Priority to EP96917844A priority Critical patent/EP0839043A2/en
Priority to AU60252/96A priority patent/AU6025296A/en
Publication of WO1996037207A2 publication Critical patent/WO1996037207A2/en
Publication of WO1996037207A3 publication Critical patent/WO1996037207A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

Compositions and methods for modulating substance P and preventing and/or treating conditions associated with substance P are disclosed. In one embodiment, compositions and methods for preventing and/or treating periodontal disease, such as gingivitis and periodontitis, are disclosed. Compositions of this invention include a calcium sulfate compound in combination with a pharmaceutically acceptable carrier or diluent. Representative calcium sulfate compounds include syngenite and görgeyite. Methods for making syngenite and görgeyite are also disclosed.
PCT/US1996/007874 1995-05-25 1996-05-28 Pharmaceutical compositions containing calcium sulfate Ceased WO1996037207A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP96917844A EP0839043A2 (en) 1995-05-25 1996-05-28 Pharmaceutical compositions containing calcium sulfate
AU60252/96A AU6025296A (en) 1995-05-25 1996-05-28 Pharmaceutical compositions containing calcium sulfate

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US45026195A 1995-05-25 1995-05-25
US08/449,949 1995-05-25
US08/450,261 1995-05-25
US08/449,949 US5683725A (en) 1995-05-25 1995-05-25 Modulation of substance P by compounds containing calcium sulfate and methods relating thereto
US52924495A 1995-09-15 1995-09-15
US08/529,244 1995-09-15

Publications (2)

Publication Number Publication Date
WO1996037207A2 WO1996037207A2 (en) 1996-11-28
WO1996037207A3 true WO1996037207A3 (en) 1997-02-27

Family

ID=27412423

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/007874 Ceased WO1996037207A2 (en) 1995-05-25 1996-05-28 Pharmaceutical compositions containing calcium sulfate

Country Status (3)

Country Link
EP (1) EP0839043A2 (en)
AU (1) AU6025296A (en)
WO (1) WO1996037207A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267962B1 (en) 1990-12-21 2001-07-31 C-P Technology Limited Partnership Compositions and methods of treatment using peat derivatives
EP0977573A1 (en) * 1997-04-24 2000-02-09 MERCK SHARP & DOHME LTD. Use of an nk-1 receptor antagonist and an ssri for treating obesity
JP2001524960A (en) * 1997-04-24 2001-12-04 メルク シヤープ エンド ドーム リミテツド Use of an NK-1 receptor antagonist to treat an eating disorder
GB9816897D0 (en) * 1998-08-04 1998-09-30 Merck Sharp & Dohme Therapeutic use

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4689223A (en) * 1986-04-24 1987-08-25 T & R Chemicals, Inc. Method of treating the symptoms of the common cold
US4735802A (en) * 1986-05-05 1988-04-05 Le Bich N Topical dermatological composition and method of treatment
WO1988009665A1 (en) * 1987-06-01 1988-12-15 Allergan, Inc. Preservative free ophthalmic ointments
US4915936A (en) * 1988-10-31 1990-04-10 United States Gypsum Company Dental hygiene composition for reducing periodontal disease
WO1994009798A1 (en) * 1992-10-29 1994-05-11 C-P Technology Limited Partnership Mixtures or complexes containing calcium and sulfate
WO1995005752A1 (en) * 1993-08-24 1995-03-02 Kappa Pharmaceuticals Limited Reduced absorption of fatty acids
JPH0899848A (en) * 1994-10-03 1996-04-16 Yoshinori Akiyama Remedial agent for pyorrhea alveolaris

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4689223A (en) * 1986-04-24 1987-08-25 T & R Chemicals, Inc. Method of treating the symptoms of the common cold
US4735802A (en) * 1986-05-05 1988-04-05 Le Bich N Topical dermatological composition and method of treatment
WO1988009665A1 (en) * 1987-06-01 1988-12-15 Allergan, Inc. Preservative free ophthalmic ointments
US4915936A (en) * 1988-10-31 1990-04-10 United States Gypsum Company Dental hygiene composition for reducing periodontal disease
WO1994009798A1 (en) * 1992-10-29 1994-05-11 C-P Technology Limited Partnership Mixtures or complexes containing calcium and sulfate
WO1995005752A1 (en) * 1993-08-24 1995-03-02 Kappa Pharmaceuticals Limited Reduced absorption of fatty acids
JPH0899848A (en) * 1994-10-03 1996-04-16 Yoshinori Akiyama Remedial agent for pyorrhea alveolaris

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 9625, Derwent World Patents Index; Class B06, AN 96-246881, XP002015614 *

Also Published As

Publication number Publication date
AU6025296A (en) 1996-12-11
EP0839043A2 (en) 1998-05-06
WO1996037207A2 (en) 1996-11-28

Similar Documents

Publication Publication Date Title
IE890357L (en) Method for Preventing Secondary Effects
HU9601555D0 (en) Process for the preparation of microcapsule compositions
CY2369B1 (en) Substituted heterocyclic compounds, preparation method therefor and pharmaceutical compositions containing same.
ZA933768B (en) Novel phosphonosulfonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism metabolism.
ZA997733B (en) Hydrazide compounds, a process for their preparation and pharmaceutical compositions containing them.
ZA968956B (en) Substituted 2,4-imidazolidinedione compounds as pharmaceutical active ingredients
HUP0003305A3 (en) Hiv protease inhibiting tetrahydro-pyrimid-2-on derivative, pharmaceutical compositions containing it and process for producing the compound
ZA964337B (en) Pharmaceutical compositions containing irbesartan.
HUP9900055A3 (en) 4-aryl-1-phenylalkyl-1,2,3,6-tetrahydropyridin -derivatives, process for producing them and pharmaceutical compositions containing them
HUP9901209A3 (en) Opioid-like peptide compounds, process for producing them and pharmaceutical compositions containing them
HUP9601034A2 (en) Aryl-alkyl-pyridazinone compounds, process for producing them, and pharmaceutical compositions containing them
EG24080A (en) New arylglycineamide derivatives, process for thw manufacture thereof and pharmaceutical compositions containing these compounds
EP0807633A3 (en) Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones
IL105717A0 (en) 7beta substituted-4-aza-5alpha-cholestan-3-ones and pharmaceutical compositions containing them
IL117091A0 (en) Methylphenyloxazolidinone derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
IL118426A0 (en) Pharmaceutical composition containing 1,3-bis-triazolyl-2- propanol derivative
ZA964374B (en) A pharmaceutical compositions for inhibiting the growth of cancers.
ZA961138B (en) Solid active ingredient compositions containing hydroxypropylcellulose.
WO1994023691A3 (en) Oral compositions for treating plaque and gingivitis containing a noncationic antibacterial agent and a bicarbonate salt
HUP9701660A3 (en) 10,13,15-trioxatricyclo[9.2.1.1.9.6]pentadekanon derivatives, process for producing them, and pharmaceutical compositions containing them
HUP9801133A3 (en) 1,2,4-triazole-derivatives, fungicide compositions containing these compounds as active ingredients
WO1996037207A3 (en) Pharmaceutical compositions containing calcium sulfate
IL120966A (en) 1, 4 - diaryl - 2 - fluoro - 2 - butene compounds, compositions containing them, processes for the preparation of such compounds and methods of using such compounds and compositions for the control of insect and acarid petsts
HUP9601976A2 (en) 4-fluoralkyl benzoylguanidines, process for producing them and pharmaceutical compositions containing these compounds
IL105474A0 (en) Pharmaceutical compositions containing 1alpha,25-dihydroxy-22(e)-dehydrovitamin d3 for treating osteoporosis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996917844

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1996917844

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1996917844

Country of ref document: EP